143,911 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by GSA Capital Partners LLP

GSA Capital Partners LLP bought a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) during the 2nd quarter, Holdings Channel.com reports. The firm bought 143,911 shares of the company’s stock, valued at approximately $527,000.

Several other institutional investors also recently bought and sold shares of FULC. Mirae Asset Global Investments Co. Ltd. bought a new position in Fulcrum Therapeutics during the fourth quarter valued at about $30,000. Meeder Asset Management Inc. bought a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth about $39,000. Quarry LP bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth about $35,000. Persistent Asset Partners Ltd acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter valued at about $75,000. Finally, Summit Securities Group LLC acquired a new position in shares of Fulcrum Therapeutics during the 1st quarter valued at about $53,000. 89.83% of the stock is currently owned by institutional investors.

Insider Transactions at Fulcrum Therapeutics

In other Fulcrum Therapeutics news, Director Alan Ezekowitz sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $3.65, for a total value of $65,700.00. Following the sale, the director owned 10,927 shares of the company’s stock, valued at $39,883.55. This trade represents a 62.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 7.30% of the stock is owned by company insiders.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ:FULC opened at $3.85 on Friday. The company has a market cap of $293.75 million, a P/E ratio of -3.18 and a beta of 3.05. The stock’s 50-day moving average is $3.70 and its 200-day moving average is $6.24. Fulcrum Therapeutics, Inc. has a 52-week low of $2.83 and a 52-week high of $15.74.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). As a group, equities analysts predict that Fulcrum Therapeutics, Inc. will post -0.69 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on FULC shares. Leerink Partners lowered Fulcrum Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.00 target price for the company. in a report on Tuesday, June 2nd. Jefferies Financial Group set a $4.00 price target on Fulcrum Therapeutics in a report on Tuesday, June 2nd. Wall Street Zen raised shares of Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price target on the stock. in a research report on Tuesday, June 2nd. Finally, Cantor Fitzgerald cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, seven have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, Fulcrum Therapeutics presently has a consensus rating of “Reduce” and a consensus target price of $8.20.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.